Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma-Reference-Cited by-同舟云学术

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Published:2015-09-17 Issue:12 Volume:126 Page:1452-1461
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Rook Alain H.¹,Gelfand Joel M.¹,Wysocka Maria¹,Troxel Andrea B.¹,Benoit Bernice¹,Surber Christian²³,Elenitsas Rosalie¹,Buchanan Marie A.¹,Leahy Deborah S.¹,Watanabe Rei⁴⁵,Kirsch Ilan R.⁶,Kim Ellen J.¹,Clark Rachael A.⁵⁷

Affiliation:

1. Department of Dermatology and the Center for Clinical Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

2. Department of Dermatology, University Hospital, Zürich, Switzerland;

3. Department of Dermatology, University Hospital, Basel, Switzerland;

4. Department of Dermatology, University of Tokyo, Tokyo, Japan;

5. Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA;

6. Adaptive Biotechnologies, Seattle, WA; and

7. Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA

Abstract

Key Points Topical resiquimod is a safe, effective therapy for early-stage CTCL that can clear both treated and untreated skin lesions. Responding patients had T-cell recruitment into skin, enhanced T-cell effector functions, and eradication of the malignant T-cell clones.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/12/1452/1387961/1452.pdf

Reference24 articles.

1. The pathogenesis of mycosis fungoides.;Girardi;N Engl J Med,2004

2. Immunopathogenesis and therapy of cutaneous T cell lymphoma.;Kim;J Clin Invest,2005

3. WHO-EORTC classification for cutaneous lymphomas.;Willemze;Blood,2005

4. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).;Olsen;Blood,2007

5. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression.;Kim;Arch Dermatol,2003

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy;Journal of Controlled Release;2024-08

2. Versatile hydrogel-based drug delivery platform for multimodal cancer therapy from bench to bedside;Applied Materials Today;2024-08

3. ROS-responsive TLR7/8 nanoagonist and ultrasound modulate dendritic cells antigen presentation;Nano Today;2024-08

4. TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation;BMC Immunology;2024-07-25

5. TLR Agonists Modify NK Cell Activation and Increase Its Cytotoxicity in Acute Lymphoblastic Leukemia;International Journal of Molecular Sciences;2024-07-08